Article Versions Notes

Kuhn PM, Russo GC, Crawford AJ, Venkatraman A, Yang N, Starich BA, Schneiderman Z, Wu P-H, Vo T, Wirtz D, et al. Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer. Pharmaceutics. 2024; 16(8):981. https://doi.org/10.3390/pharmaceutics16080981

Kuhn, Paul M., Gabriella C. Russo, Ashleigh J. Crawford, Aditya Venkatraman, Nanlan Yang, Bartholomew A. Starich, Zachary Schneiderman, Pei-Hsun Wu, Thi Vo, Denis Wirtz, and et al. 2024. "Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer" Pharmaceutics 16, no. 8: 981. https://doi.org/10.3390/pharmaceutics16080981

Kuhn, P. M., Russo, G. C., Crawford, A. J., Venkatraman, A., Yang, N., Starich, B. A., Schneiderman, Z., Wu, P. -H., Vo, T., Wirtz, D., & Kokkoli, E. (2024). Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer. Pharmaceutics, 16(8), 981. https://doi.org/10.3390/pharmaceutics16080981